**MEDICINES CONTROL AGENCY**

Kairaba Avenue, K.S.M.D. Pipeline, The Gambia. Telephone: (+220)4380632, [www.mca.gm](http://www.mca.gm)

|  |
| --- |
| SECTION A ADMINISTRATIVE INFORMATION |
| **Title of Clinical Trial:**  |
| **Sponsor:** (*Please insert name and address),* |
| **Principal Investigator:** (*Please insert name, address, email, phone*)  |
| Protocol Number  |  | MCA CT Number  |  |
| PACTR Number  |  | Other  |  |
| Date of Start of the Trial: |  |
| Date of End of the Trial: |  |
| Date of interim data analysis, if any: |  |
| Date of final data analysis: |  |
| Was it an early termination | Yes |  | No |  |
| **Date of this report:**  |

|  |
| --- |
| SECTION B General Information about the Clinical Trial |
| **Main objectives of the trial:** |
| Trial design: |
| Scientific background and explanation of rationale: |
| Measures of protection of subjects taken: |
| Background therapy: |
| Statistical methods used: |

|  |
| --- |
| SECTION C Population of subjects in The Gambia |
| **Inclusion criteria** |  |
| **Exclusion criteria** |  |
| **Number of subjects screened** |  |
| Number of subjects recruited  |  |
| **Number of subjects included in the clinical trial** |  |
| Number of subjects withdrawn |  |

|  |
| --- |
| SECTION D Investigational Products  |
| Description of investigational products used: |
| Randomisation details: |
| Blinding details (if applicable): |
| Accountability (repeat information for each product): |
| Total quantity importedTotal quantity purchased locallyTotal quantity used in the trialTotal quantity wasted (spilled/lost)Total quantity onsite (if applicable)Total quantity returned to sponsorTotal quantity disposed |  |

|  |
| --- |
| SECTION E Baseline Characteristics |
| Age and age group breakdown |  |
| Gender and gender breakdown |  |
| Study Specific Characteristic (if applicable) |  |

|  |
| --- |
| SECTION F End Points |
| End point definitions\*: |
| End Point #1 Statistical Analyses: |
| End Point #2 Statistical Analyses: |

\*Information shall be provided for as many end points as defined in the protocol

| SECTION G Adverse Events |
| --- |
| Description of overall adverse event experience: |
| Summary and narratives of serious adverse events, indicating those suspected to be related to the IP (attach tables) |
| Summary of non-serious adverse events (attach tables) |

|  |
| --- |
| SECTION H Additional Information |
| Substantial Modifications: |
| Interruptions and re-starts |  |
| Limitations: |
| Sources of potential bias and imprecisions: |
| *For clinical trials replicating studies on already authorised investigational products and used in accordance with the terms of the marketing authorisation* |
| Indicate identified concerns to relevant aspects of the efficacy of the IP |

|  |
| --- |
| SECTION I overall results of the clinical trial |
|  |

**List the documents attached to this report**

I, the undersigned certify that this clinical trial was conducted in compliance with ICH E6-GCP Guideline including the archiving of essential documents, and any applicable regulatory requirements, and that the information submitted in this report is accurate.

Signature of Principal Investigator in The Gambia:

 Signature Date